Patents by Inventor Erin Gainer

Erin Gainer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for on-demand contraception
    Patent number: 10772897
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 15, 2020
    Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • METHOD FOR ON-DEMAND CONTRACEPTION
    Publication number: 20190209583
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 11, 2019
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • COPPER INTRAUTERINE DEVICE
    Publication number: 20190008763
    Abstract: The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 10, 2019
    Inventors: Andre ULMANN, Erin GAINER, Delphine LEVY, Christine Seguin, Florian Battung, Regine SITRUK-WARE
  • Method for on-demand contraception
    Patent number: 10159681
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: December 25, 2018
    Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • ULIPRISTAL ACETATE TABLETS
    Publication number: 20180064651
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Method for scheduling ovulation
    Patent number: 9855282
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: January 2, 2018
    Assignee: Laboratoire HRA-Pharma
    Inventors: Delphine Levy, Erin Gainer
  • Ulipristal acetate tablets
    Patent number: 9844510
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 19, 2017
    Assignee: Laboratoire HRA-Pharma
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Ulipristal acetate for prevention and treatment of breast tumors
    Patent number: 9814732
    Abstract: The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 14, 2017
    Assignees: Laboratoire HRA-PHARMA, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Michele Resche-Rigon, Delphine Levy, Erin Gainer, Anne Gompel, Patricia Forgez, Laudine Desreumaux-Communal
  • METHOD FOR TREATING UTERINE FIBROIDS
    Publication number: 20170246189
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl) -19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 31, 2017
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • Method for treating uterine fibroids
    Patent number: 9682088
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 20, 2017
    Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • Method for providing regular contraception
    Publication number: 20170136036
    Abstract: The invention relates to a method for providing regular contraception to a woman. Said method comprises administering a daily contraceptive amount of ulipristal acetate or a metabolite thereof over a period of at least 21 consecutive days.
    Type: Application
    Filed: July 2, 2015
    Publication date: May 18, 2017
    Inventors: Delphine LEVY, Erin GAINER, Andre ULMANN
  • Method for on-demand contraception
    Patent number: 9616073
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: April 11, 2017
    Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Lynnette Nieman, Diana Blithe
  • METHOD FOR SCHEDULING OVULATION
    Publication number: 20170056417
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventors: Delphine LEVY, Erin GAINER
  • ULIPRISTAL ACETATE FOR PREVENTION AND TREATMENT OF BREAST TUMORS
    Publication number: 20170014426
    Abstract: The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.
    Type: Application
    Filed: July 29, 2016
    Publication date: January 19, 2017
    Inventors: Michele RESCHE-RIGON, Delphine LEVY, Erin GAINER, Anne GOMPEL, Patricia FORGEZ, Laudine DESREUMAUX-COMMUNAL
  • Method for scheduling ovulation
    Patent number: 9522154
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 20, 2016
    Assignee: LABORATOIRE HRA-PHARMA
    Inventors: Delphine Levy, Erin Gainer
  • METHOD FOR ON-DEMAND CONTRACEPTION
    Publication number: 20160317555
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Application
    Filed: February 5, 2016
    Publication date: November 3, 2016
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • ULIPRISTAL ACETATE TABLETS
    Publication number: 20160287518
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Application
    Filed: June 17, 2016
    Publication date: October 6, 2016
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Method for on-demand contraception
    Patent number: 9283233
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: March 15, 2016
    Assignees: LABORATOIRE HRA-PHARMA, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • METHOD FOR TREATING UTERINE FIBROIDS
    Publication number: 20160022698
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Application
    Filed: October 1, 2015
    Publication date: January 28, 2016
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • METHOD FOR SCHEDULING OVULATION
    Publication number: 20160022697
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Delphine LEVY, Erin GAINER